Compare Abbott Laboratories (ABT) vs Celestica Inc (CLS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Celestica Inc — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Celestica Inc trades at $352.02 (market cap $39.70B). The key difference: Abbott Laboratories is far larger — about 4.2× Celestica Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Celestica Inc pays none. Which is the better fit depends on your goals.
| ABT | CLS | |
|---|---|---|
Market Cap | $166.94B | $39.70B |
Sector | Health | Technology |
52-Week High | $136.62 | $472.40 |
52-Week Low | $82.57 | $155.70 |
Enterprise Value | $193.69B | $40.10B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Celestica (CLS) trades at $350.20, up 4.16% over 24 hours, with a bearish technical signal and neutral oscillators. The company shows strong fundamental momentum with three consecutive quarterly EPS beats and robust profitability metrics, including a 52.45% ROE. Recent leadership appointments in cloud solutions and positive analyst coverage highlight growth potential amid competitive pressures.
The stock presents a compelling growth opportunity with a consensus price target of $440.10, implying 25% upside, supported by AI and data center demand. Key risks include margin pressures, technical bearish signals, and reliance on execution amid industry competition. Investors should weigh strong earnings trajectory against near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →
